JAC Advance Access originally published online on January 16, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2004) 53, 318-324
© 2004 The British Society for Antimicrobial Chemotherapy
Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli
Institute for Medical Microbiology and Epidemiology of Infectious Diseases, University of Leipzig, Liebigstr. 24, D-04103 Leipzig, Germany
Received 30 June 2003; returned 3 September 2003; revised 14 October 2003; accepted 27 November 2003
Objectives: To study the effect of moxifloxacin versus imipenem/cilastatin (hereafter referred to as imipenem) treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli.
Methods: Groups of 20 mice each were infected intravenously with different strains of B. fragilis [moxifloxacin and imipenem susceptible or resistant, and enterotoxin (ET) positive or negative] and E. coli (moxifloxacin and imipenem susceptible). Twenty-four hours post-infection, intravenous therapy with either moxifloxacin (2.0 mg twice a day) or imipenem (2.4 mg three times a day) was started and continued for 3 days. Control groups were left untreated. Survival rates were recorded at day 7 post-infection. At that time, surviving mice were killed and numbers of bacteria in the liver and kidneys were determined.
Results: If compared with untreated animals, mice treated with either moxifloxacin or imipenem showed significantly improved survival (P < 0.001). There was no significant difference (P = 0.97) in the survival rates comparing the two treatment regimens irrespective of the ET positivity or the susceptibility to moxifloxacin or imipenem of the infective B. fragilis strain. However, there was a tendency that B. fragilis was recovered more often from the liver and kidneys of mice infected with ET positive strains.
Conclusions: The data show that moxifloxacin was as efficacious as imipenem in reducing the mortality rate of mice suffering from a severe systemic aerobic/anaerobic infection.
Keywords: aerobic/anaerobic infections, mouse model of infection, treatment of mixed infections
* Corresponding author. Tel: +49-341-97-15-200; Fax: +49-341-97-15-209; E-mail: schaur{at}medizin.uni-leipzig.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. J. C. Goldstein, D. M. Citron, Y. A. Warren, K. L. Tyrrell, C. V. Merriam, and H. Fernandez In Vitro Activity of Moxifloxacin against 923 Anaerobes Isolated from Human Intra-Abdominal Infections Antimicrob. Agents Chemother., January 1, 2006; 50(1): 148 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. R. Noel, K. E. Bowker, and A. P. MacGowan Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model Antimicrob. Agents Chemother., October 1, 2005; 49(10): 4234 - 4239. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Schaumann, E. J. Goldstein, J. Forberg, and A. C Rodloff Activity of moxifloxacin against Bacteroides fragilis and Escherichia coli in an in vitro pharmacokinetic/pharmacodynamic model employing pure and mixed cultures J. Med. Microbiol., August 1, 2005; 54(8): 749 - 753. [Abstract] [Full Text] [PDF]
|
|